Auristatin E

• Description :

  Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC) . Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids[1][2][3].

• UNSPSC :

  12352203

• Hazard Statement :

  H341, H361, H372

• Target :

  ADC Payload; Microtubule/Tubulin

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Auristatin-E.html

• Purity :

  99.89

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C)[C@H](N(C)C)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)C(C)C)=O

• Molecular Formula :

  C40H69N5O7

• Molecular Weight :

  732.01

• Precautions :

  H341, H361, H372

• References & Citations :

  [1]MADDON Paul J, et al. PSMA ANTIBODIES AND PROTEIN MULTIMER. 2002 October 23. WO 03/034903 A2|[2]Peter D. Senter, et al. PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO. 2005 Jan. 13. US 2005/0009751 A l.|[3]LAW, Che-Leung, et al. TREATMENT OF IMMUNOLOGICAL DISORDERS 5 USING ANTI-CD30 ANTIBODIES. 2002 November 20. WO 03/043583 A2.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• Isoform :

  Auristatin

• CAS Number :

  [160800-57-7]